St. Louis, Missouri
August 6, 2008
Monsanto Company (NYSE: MON) announced today that it is
pursuing a divestiture of its dairy product,
POSILAC® bovine somatotropin, in the upcoming months. Additional
details have not been disclosed at this time.
"While POSILAC is a strong product for the business, we believe
repositioning the business with a strategic owner will allow
Monsanto to focus on the growth of its core seeds and traits
business while ensuring that loyal dairy farmers continue to
receive the value of POSILAC in their operations," said Carl
Casale, Monsanto's Executive Vice-President of Strategy and
Operations.
POSILAC is an FDA-approved animal pharmaceutical used by U.S.
dairy farmers to increase productivity. Since it was first sold
in the United States in 1994, POSILAC has become the country's
leading dairy animal supplement.
Supplementing dairy cows with POSILAC safely enhances milk
production and serves as an important tool to help dairy
producers improve the efficiency of their operations and produce
more milk more sustainably. POSILAC helps farmers with herds of
all sizes produce more milk per cow. This increase in production
provides dairy farmers with additional economic security by
increasing the return on their overall investment. Cows
supplemented with POSILAC produce an average of 10 lb. more milk
per day.
A recent study conducted by several researchers at Cornell
University highlighted the role of POSILAC as an on-farm dairy
tool that can effectively reduce the environmental impact of
dairy operations. The Cornell study can be accessed online at
http://www.ansci.cornell.edu/bauman/envir_impact/.
Monsanto Company is a leading global provider of
technology-based solutions and agricultural products that
improve farm productivity and food quality.
POSILAC® is a registered trademark of Monsanto Company and its
wholly-owned subsidiaries. |
|
